stockrow
Friday 6 November 2026
Export RLYB’s income statement to Excel — free account
Rallybio Corporation
RLYB Healthcare Biotechnology
Rallybio Corporation’s revenue for fiscal 2025 (year ended December 2025) was $858,000.00, up 34.9% from fiscal 2024.
- Revenue
- 0.00%
- EPS
- −116.6%
- Free cash flow
- +65.3%
Quarter to September 2026, against a year earlier
15.74
0.16
−1.01%
Follow RLYB
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(15.01%) | (14.98%) | 64.86% | 34.52% | |
| (13.77%) | (13.90%) | 61.12% | 32.85% | ||
ROIC |
(641.77%) | (576.66%) | (1,052.03%) | (944.36%) | |
Return on Tangible Assets |
(15.74%) | (15.83%) | 48.62% | 29.31% | |
Average Days of Receivables |
0.00 | 0.00 | — | — | |
Free Cash Flow per Share |
(5.30) | (4.85) | 4.69 | 5.42 | |
Free Cash Flow |
(29.81) | (27.59) | 26.71 | 30.99 | |
| Other line items | |||||
Cash ROIC |
(26.46%) | (28.42%) | 14.26% | 16.93% | |
Accounts Receivable Turnover |
0.00 | 0.00 | — | — | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | (0.03) | (0.05) | |
Research and Development Expense of Revenue |
2,284.03% | 1,951.40% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
1,669.58% | 1,893.01% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
619.35% | 471.79% | 0.00% | 0.00% | |
Operating CF/Net income |
3.32 | 3.53 | 0.59 | 1.16 | |
Depreciation/Fixed assets |
(20.91) | (17.35) | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.15 | 0.15 | 0.00 | 0.00 | |
Operating CF per Share |
(5.30) | (4.85) | 4.69 | 5.42 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | — | — |
Columns are period end dates · fundamentals updated 2 Nov 2026